Patents Examined by Claire Kaufman
  • Patent number: 11407801
    Abstract: Provided herein are SIRP-gamma, SIRP-beta or SIRP-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: August 9, 2022
    Assignee: Ab Initio Biotherapeutics, Inc.
    Inventors: Aaron Michael Ring, Roy Louis Maute, Andrew Curtis Kruse, Aashish Manglik, Kenneth S. Lin
  • Patent number: 11384153
    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: July 12, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Eric Smith, Kara Olson, Frank Delfino, David DiLillo, Jessica Kirshner, Olga Sineshchekova, Qian Zhang
  • Patent number: 11377490
    Abstract: Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond-linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 5, 2022
    Assignee: Sichuan Clover Biopharmaceuticals, Inc
    Inventor: Peng Liang
  • Patent number: 11370840
    Abstract: The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to CD47 (Cluster of Differentiation 47, also known as integrin associated protein [IAP]). In aspects of the invention, the anti-CD47 antibody molecules and antigen-binding portions thereof specifically bind to human CD47 and cynomolgus monkey CD47. Medical uses of the anti-CD47 antibody molecules and antigen-binding portions of the invention are disclosed. The anti-CD47 antibody molecules and antigen-binding portions of the invention represent modified and optimised binding molecules compared with a VxP037 murine/humanized anti-CD47 antibody described in WO2014/093678A2.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: June 28, 2022
    Assignee: ULTRAHUMAN FOUR LIMITED
    Inventor: William James Jonathan Finlay
  • Patent number: 11365236
    Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: June 21, 2022
    Assignees: NKARTA, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
  • Patent number: 11359024
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: June 14, 2022
    Assignees: PFIZER INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akhurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
  • Patent number: 11352404
    Abstract: Fusion molecules of a cytokine or portion thereof and a polypeptide which targets the fusion protein to phosphatidylserine, pharmaceutical compositions thereof, and methods for their use in targeting a cytokine or portion thereof to a pathological site and treating a disease or condition responsive to cytokine treatment are provided.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: June 7, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sergei V. Kotenko, Raymond B. Birge, Viralkumar Rameshkumar Davra
  • Patent number: 11352429
    Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: June 7, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • Patent number: 11339218
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti-LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: May 24, 2022
    Assignee: Zhejiang Shimai Pharmaceutical Co., Ltd.
    Inventors: Weizao Chen, Tao Fu, Zuoxiang Xiao
  • Patent number: 11339222
    Abstract: A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 24, 2022
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Steven Greenberg, Stefano Vincenzo Gulla, Kenneth Evan Thompson
  • Patent number: 11292849
    Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: April 5, 2022
    Assignee: Eucure (Beijing) Biopharma Co., Ltd.
    Inventors: Yi Yang, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen
  • Patent number: 11278587
    Abstract: The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 22, 2022
    Assignee: 9 METERS BIOPHARMA, INC.
    Inventors: Jay Madan, Sandeep Laumas
  • Patent number: 11274151
    Abstract: The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: March 15, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Sotaro Naoi, Shu Feng, Tomoyuki Igawa, Shu Wen Samantha Ho
  • Patent number: 11254716
    Abstract: A polypeptide having a sequence at least 60% identical to SEQ ID NO: 1 (WFEWPYWEMNVPDVWN) is provided. The polypeptide includes no more than 100 total amino acid residues.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: February 22, 2022
    Assignee: 3M Innovative Properties Company
    Inventors: Minghua Dai, Amy K. McNulty, Federica Sgolastra, Jie Liu, Jana Ninkovic, Robert T. Fitzsimons, Jr.
  • Patent number: 11241480
    Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for modulation of dietary and microbial exposure. The present disclosure provides for compositions and methods for treating, preventing, or reducing the likelihood of development of an allergic disorder, necrotizing enterocolitis, sepsis, or an inflammatory disease, disorder, or condition in a subject including administering an effective amount of a composition comprising an EGFR ligand.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 8, 2022
    Assignee: Washington University
    Inventors: Rodney Newberry, Kathryn Knoop, Keely McDonald
  • Patent number: 11236144
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 1, 2022
    Assignee: VERSITECH LIMITED
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
  • Patent number: 11230605
    Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 25, 2022
    Assignee: INATHERYS
    Inventors: Pierre Launay, Coralie Belanger, Hervé Souchet
  • Patent number: 11230579
    Abstract: The present invention provides an antagonist of a Bcl-2 prosurvival protein containing a BH3-like domain. The antagonist of the invention comprises ARTS and any fragment or peptide that comprises a BH3-like domain. The invention further provides compositions, combined compositions and kits as well as methods for treating Bcl-2 over-expressing disorders.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 25, 2022
    Assignee: CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD.
    Inventor: Sarit Larisch
  • Patent number: 11220549
    Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: January 11, 2022
    Assignee: Cephalon, Inc.
    Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget A. Cooksey, Vanya Pande, Adam W. Clarke
  • Patent number: 11214622
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: January 4, 2022
    Assignee: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser